Effect of the anticancer drug methotrexate on the ascites form of a teratocarcinoma and survival of mice

Abstract

The dose-dependent effect of a methotrexate is established as on an ascite form of a teratocarcinoma CBA9H6, and mice-recipients, however various doses of the entered methotrexate (6; 4 and 2 mkg/g body weights of an animal), at repeated introduction at an interval of 48 and 24 hours, don't destroy all population of embrioid bodies. So, at 3-fold and even 10-fold daily injections in a dose of 2 mkg/g of body weight in an abdominal cavity of mice 1,6 ± 0,2% and 0,038 ± 0,01% embrioid bodies (ascite form of a teratocarcinoma ) remain, respectively, at survival of mice 93,0 ± 8,5% and 14,0 ± 3,0%. The morphological analysis of a mode of a differentiation of embrioid bodies retransplantated from experimental animals to intact has shown earlier that the methotrexate hasn't had effect on histoblastic potentialities of stem cells of a teratocarcinoma CBA9H6.

Keywords

action of a methotrexate / ascite form of a teratocarcinoma CBA9H6 / mice

References

[1] Дыбан П.А. Использование тератом мышевидных грызунов для исследования механизмов цитодифференцировки и гистогенеза // Опухолевый рост как проблема биологии развития / Под ред. В.И. Гельштейна. - М.: Наука, 1979. - С. 174-207. [Dyban P. The use of teratomas of rodents to study the mechanisms of cytodifferentiation and histogenesis. In: Tumor growth as a problem of developmental biology. Ed by V.I. Gelstein. Moscow: Science; 1979. P. 174-207. (In Russ.)]

[2] Дыбан П.А. Особенности роста и дифференцировки тератокарциномы OC15S1 в сингенных и аллогенных мышах // Бюллетень экспериментальной биолологии и медицины. - 1984. - № 1. - С. 71-72. [Dyban PA. Peculiarities of the growth and differentiation of teratocarcinoma OC15S1 in syngeneic and allogeneic mice. Bull Exp Biol Med.1984;(1):71-72. (In Russ.)]

[3] Родионов Г.Г., Шантырь И.И., Ушал И.Э., и др. Опыт определения концентрации противоопухолевых препаратов как способ обеспечения безопасности фармакотерапии // Обзоры по клинической фармакологии и лекарственной терапии. - 2018. - Т. 16. - № 1. - С. 64-70. [Rodionov GG, Shantyr II, Ushal IE, et al. Experience of determination of antitumour drugs content as a method of providing the safety of pharmacotherapy. Reviews on Clinical Pharmacology and Drug Therapy. 2018;16(1):64-70. doi: 10.17816/ RCF16164-70. (In Russ.)]

[4] Bertino JR, Göker E, Gorlick R, et al. Resistance mechanisms to methotrexate in tumors. Oncologist. 1996;1(4):223-226. doi: 10.1002/stem.140005.

[5] Chabner BA, Roberts TG. Jr. Chemotherapy and the war on cancer. Cancer. 2005;5:65-72.

[6] Damjanov I, Andrews PW. The terminology of teratocarcinomas and teratomas. Nature Biotechnol. 2007;25:1212. doi: 10.1038/nbt1107-1212a.

[7] Gropp M, Shilo V, Vainer G, et al. Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny. PLoS ONE. 2012;7: e45532.

[8] Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;309(18):1094-1104. doi: 10.1056/NEJM198311033091805.

[9] Osborn MJ, Freeman M, Huennekens FM. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med. 1958;97:429-431. doi: 10.3181/00379727-97-23764.

[10] Osborn MJ, Huennekens FM. Enzymatic reduction of dihydrofolic acid. J Biol Chem. 1958;233:969-974.

[11] Pierce GB. Teratocarcinoma: model for a developmental concept of cancer. Curr Top Dev Biol. 1967;2:223-246. doi: 10.1016/S0070-2153(08)60289-6.

[12] Solter D. From teratocarcinomas to embryonic stem cells and beyond: A history of embryonic stem cell research. Nat Rev Genet. 2006;7:319-327.

[13] Zulfequar A, Tripathi R, Brahmeshwar M. Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opinion on Drug Delivery. 2012;9(2):151-169. doi: 10.1517/17425247. 2012. 642362.

RIGHTS & PERMISSIONS

Dyban P.A.